• If you are citizen of an European Union member nation, you may not use this service unless you are at least 16 years old.

  • Stop wasting time looking for files and revisions. Connect your Gmail, DriveDropbox, and Slack accounts and in less than 2 minutes, Dokkio will automatically organize all your file attachments. Learn more and claim your free account.


Study shows Chagas drug efficacy and gives new way to assess effects in humans

Page history last edited by Rosemary 12 years, 5 months ago


Research shows that the main drug treatment for Chagas disease can completely rid chronically infected hosts of the disease-causing parasite. The researchers say this provides the first evidence that the drug can be so effective. The study also suggests a new way of assessing the efficacy of drugs for the disease.

Current therapies are limited in their use due to potentially severe side effects and doubts surrounding their effectiveness. Some drug treatments are thought to be effective in less than 50 per cent of patients. But the new study found that benznidazole — the principle drug used to treat Chagas disease — can completely clear Trypanosoma cruzi parasites in a mouse model.

"I would hope that the proof of efficacy reported in our study will prompt wider use of the available drugs to treat chronically infected individuals," says Rick Tarleton, lead author of the study from the US-based University of Georgia

The study also measured the population of CD8 T cells — a type of immune cell — specific to the parasite in the blood. The researchers found that successful treatment of the parasite led to the emergence of a stable population of T. cruzi-specific T cells. These were able to mount an effective immune response against re-infection.

The researchers suggest that monitoring CD8 T cells could be a useful marker to evaluate the efficacy of new Chagas drugs in humans — a marker which they say is lacking in current Chagas drug development. If a treatment works, T cells specific to T. cruzi would be detected.

"Our work shows that we have an experimental model and a 'gold standard' treatment [beznidazole] against which to compare other new drugs. If they do not work as well as benznidazole, they probably should not be pursued in human trials," says Tarleton.

The research was published in the online edition of the journal Nature Medicine.

Chagas disease affects 16–18 million people throughout Latin America.



Full paper in Nature Medicine

Ref: Nature Medicine doi 10.1038/nm1744 (2008)

This story, entitled Study 'proves' Chagas drug efficacy, was written by Paula Leighton and distributed by SciDev.Net on 6 May 2008. SciDev.Net – the Science and Development Network – is a not-for-profit organisation dedicated to providing reliable and authoritative information about science and technology for the developing world.  Its website gives policymakers, researchers, the media and civil society information and a platform to explore how science and technology can reduce poverty, improve health and raise standards of living around the world.


Comments (0)

You don't have permission to comment on this page.